Restricted accessReview articleFirst published online 2018-4
Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters
Anti-John Cunningham virus (JCV) serology has been studied with varying results concerning longitudinal changes.
Objectives and methods:
Results from 17 published natalizumab-treated multiple sclerosis (MS) patient cohorts were analyzed with common parameters and subsequently verified in two large independent cohorts with 722 and 499 patients from Germany and the United States.
Results:
Published studies and the verification showed (1) a mean of 10.80% sero-negative patients presented with sero-status change to positivity per year; (2) patients, who sero-convert to index values <0.9, convert from near the threshold and have a high probability of reverting with time; (3) patients, who convert to index values >0.9, start with low index values; (4) while JCV sero-positive patients with low index values sometimes revert to sero-negativity, patients with high index values almost never revert; and (5) the conversion rate of natalizumab-treated patients is three to four times higher than the biological conversion by age.
Conclusion:
JCV sero-conversion was comparable using standardized parameters and indicates influence of natalizumab on JCV immune control. Converters to low index values are probably consistently infected with JCV with varying low levels of activity, in line with their low risk to develop progressive multifocal leukoencephalopathy (PML). Patients with high index values rarely revert back to sero-negativity.
ZurheinGChouSM. Particles resembling papova viruses in human cerebral demyelinating disease. Science1965; 148(3676): 1477–1479.
2.
AstromKEMancallELRichardsonEP. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin’s disease. Brain1958; 81(1): 93–111.
3.
CliffordDBNathACinquePet al. A study of mefloquine treatment for progressive multifocal leukoencephalopathy: Results and exploration of predictors of PML outcomes. J Neurovirol2013; 19(4): 351–358.
4.
Du PasquierRAKurodaMJZhengYet al. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain2004; 127(Pt 9): 1970–1978.
5.
CinquePBossolascoSBrambillaAMet al. The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: Study of 43 cases with review of the literature. J Neurovirol2003; 9(suppl. 1): 73–80.
6.
Van AsscheGVan RanstMSciotRet al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med2005; 353(4): 362–368.
7.
Kleinschmidt-DeMastersBKTylerKL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med2005; 353(4): 369–374.
8.
Langer-GouldAAtlasSWGreenAJet al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med2005; 353(4): 375–381.
9.
GorelikLLernerMBixlerSet al. Anti-JC virus antibodies: Implications for PML risk stratification. Ann Neurol2010; 68(3): 295–303.
SchwabNSchneider-HohendorfTPignoletBet al. PML risk stratification using anti-JCV antibody index and L-selectin. Mult Scler2016; 22(8): 1048–1060.
12.
VillarLMCosta-FrossardLMastermanTet al. Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab. Ann Neurol2015; 77(3): 447–457.
LeePPlavinaTCastroAet al. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J Clin Virol2013; 57(2): 141–146.
15.
PlavinaTSubramanyamMBloomgrenGet al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol2014; 76(6): 802–812.
16.
RandhawaPZygmuntDShapiroRet al. Viral regulatory region sequence variations in kidney tissue obtained from patients with BK virus nephropathy. Kidney Int2003; 64(2): 743–747.
17.
PastranaDVBrennanDCCuburuNet al. Neutralization serotyping of BK polyomavirus infection in kidney transplant recipients. PLoS Pathog2012; 8(4): e1002650.
18.
WolleboHSWhiteMKGordonJet al. Persistence and pathogenesis of the neurotropic polyomavirus JC. Ann Neurol2015; 77(4): 560–570.
19.
BozicCRichmanSPlavinaTet al. Anti-John Cunningham virus antibody prevalence in multiple sclerosis patients: Baseline results of STRATIFY-1. Ann Neurol2011; 70(5): 742–750.
20.
TrampeAKHemmelmannCStroetAet al. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology2012; 78(22): 1736–1742.
21.
OlssonTAchironAAlfredssonLet al. Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Mult Scler2013; 19(11): 1533–1538.
22.
BozicCSubramanyamMRichmanSet al. Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial. Eur J Neurol2014; 21(2): 299–304.
23.
EgliAInfantiLDumoulinAet al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis2009; 199(6): 837–846.
24.
SrollerVHamšíkováELudvíkováVet al. Seroprevalence rates of BKV, JCV, and MCPyV polyomaviruses in the general Czech Republic population. J Med Virol2014; 86(9): 1560–1568.
25.
AntonssonAGreenACMallittK-Aet al. Prevalence and stability of antibodies to the BK and JC polyomaviruses: A long-term longitudinal study of Australians. J Gen Virol2010; 91(Pt 7): 1849–1853.
26.
HennesEMKornekBHuppkePet al. Age-dependent seroprevalence of JCV antibody in children. Neuropediatrics2016; 47(2): 112–114.
27.
SundqvistEBuckDWarnkeCet al. JC polyomavirus infection is strongly controlled by human leucocyte antigen class II variants. PLoS Pathog2014; 10(4): e1004084.
28.
International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2; SawcerSHellenthalGPirinenMet al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature2011; 476(7359): 214–219.
29.
Dominguez-MozoMIRusMSantiagoJLet al. Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort. Eur J Clin Invest2017; 47(2): 158–166.
30.
HavlaJKleiterIKümpfelT. Bridging, switching or drug holidays – How to treat a patient who stops natalizumab?Ther Clin Risk Manag2013; 9: 361–369.
31.
AlroughaniR. High discontinuation rate of natalizumab in JC virus seropositive patients due to significant anxiety and safety feelings. Mult Scler2014; 20(12): 1667–1668.
32.
PML incidence in patients receiving Tysabri (natalizumab). Biogen Idec, http://medinfo.biogenidec.com (accessed 4 November 2016).
33.
KolasaMHagmanSVerkkoniemi-AholaAet al. Anti-JC virus seroprevalence in a Finnish MS cohort. Acta Neurol Scand2016; 133(5): 391–397.
34.
Dominguez-MozoMIGarcia-MontojoMLas Heras deVet al. Anti-JCV antibodies detection and JCV DNA levels in PBMC, serum and urine in a cohort of Spanish Multiple Sclerosis patients treated with natalizumab. J Neuroimmune Pharmacol2013; 8(5): 1277–1286.
35.
BergerJRHouffSAGurwellJet al. JC virus antibody status underestimates infection rates. Ann Neurol2013; 74(1): 84–90.
36.
CampagnoloDHoPPatelRNet al. Four-year longitudinal index stability data from stratify-2 support the clinical utility of index for risk stratification of natalizumab-associated progressive multifocal leukoencephalopathy (P5.407). Neurology2016; 87(2): E25–E25.
37.
WarnkeCOlssonTHartungH-P. PML: The dark side of immunotherapy in multiple sclerosis. Trends Pharmacol Sci2015; 36(12): 799–801.
38.
WarnkeCRamanujamRPlavinaTet al. Changes to anti-JCV antibody levels in a Swedish national MS cohort. J Neurol Neurosurg Psychiatry2013; 84(11): 1199–1205.
39.
KalincikTBrownJWRobertsonNet al. Comparison of 5-year treatment outcomes between alemtuzumab versus natalizumab, fingolimod and interferon β-1a. Mult Scler2016; 22(3 suppl.): 828–883.
40.
SpelmanTKalincikTJokubaitisVet al. Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS. Neurol Clin Pract2016; 6(2): 102–115.
41.
BargielaDBianchiMTWestoverMBet al. Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis. Neurology2017; 88(7): 677–684.
42.
LanzilloRLiuzziRAmatoLet al. JC virus antibodies index on natalizumab treatment: Fluctuations and seroconversion. Mult Scler2013; 19(11 suppl.): 474–558.
43.
OutteryckOZéphirHSalleronJet al. JC-virus seroconversion in multiple sclerosis patients receiving natalizumab. Mult Scler2013; 20(7): 822–829.
44.
RaffelJGafsonARMalikOet al. Anti-JC virus antibody titres increase over time with natalizumab treatment. Mult Scler2015; 21(14): 1833–1838.
45.
DelbueSEliaFCarloniCet al. JC virus urinary excretion and seroprevalence in natalizumab-treated multiple sclerosis patients. J Neurovirol2015; 21(6): 645–652.
46.
AlroughaniRAkhtarSAhmedSFet al. JC virus seroprevalence and seroconversion in multiple sclerosis cohort: A Middle-Eastern study. J Neurol Sci2016; 360: 61–65.
47.
HoytTChristensenAMetzgerRet al. Anti-JCV antibody serostatus in a long-term natalizumab infusing population. Mult Scler2016; 22(3 suppl.): 400–705.
48.
SchwabNSchneider-HohendorfTPignoletBet al. Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values. Neurol Neuroimmunol Neuroinflamm2016; 3(1): e195.
49.
VennegoorAvan RossumJALeursCet al. High cumulative JC virus seroconversion rate during long-term use of natalizumab. Eur J Neurol2016; 23(6): 1079–1085.
50.
DonovanELaGankeC. An evaluation of the longitudinal stability of anti-JC virus (JCV) antibody levels in patients with multiple sclerosis (MS) (P3.093). Neurology2016; 86(16 suppl.): 54–55.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
